Karyopharm Therapeutics Inc.
KPTI
NASDAQ·Healthcare·Biotechnology·Mkt cap $40.6M
$1.79
▲ +1.13%
P/E
—
Mkt Cap
$40.6M
52-Wk Range
$1.72–$10.99
52-Week Range
$1.72 - $10.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 71.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary SINE (Selective Inhibitor of Nuclear Export) technology platform
- First-in-class mechanism of action targeting XPO1 protein
- FDA-approved XPOVIO with established clinical efficacy data
- Strategic international partnerships expanding market reach
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Increased XPOVIO adoption in multiple myeloma and DLBCL markets
Value
Valuation data unavailable
Momentum
Falling
-80.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KPTI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 13, 2026
Reported EPS of -$2.32 vs -$1.37 consensus (-69.3% surprise). Revenue of $33.4M vs $32.2M expected (+3.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-69.3%
Revenue trend · last 8Q
—
—
-9%
-11%
+14%
+12%
+17%
-12%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$38.8M
$30.5M
$30.0M
$37.9M
$44.0M
$34.1M
$35.1M
$33.4M
Margins · last 8Q
Gross
96.8%
Operating
-67.4%
Profit
-200.5%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
0%
Sell
25%
Median Price Target
—
Latest: HC Wainwright · Jul 31, 2026
vs Industry
How KPTI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.